Foundayo

Foundayo (orforglipron) is Eli Lilly's oral non-peptide GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity [1]. It is the first oral small-molecule drug in a class that has, until now, required injections or complex absorption-enhancer formulations. Foundayo-specific revenue has not yet been reported in Lilly's SEC filings; commercial launch occurred in Q2 2026, after the 2024 10-K filing period [2]. Lilly's total company revenue was $45.0 billion in 2024 (up 32% year over year), with its injectable GLP-1 franchise (Zepbound and Mounjaro, both tirzepatide) driving the majority of that growth per the same filing [2]. The commercial thesis is straightforward: a pill scales where an injectable cannot. Manufacturing peptides at the global demand level for GLP-1 drugs has been a hard supply constraint on the whole category. A small molecule made in standard chemical reactors, without cold-chain shipping, raises the supply ceiling. That is why Foundayo matters commercially, even though its weight-loss figures trail Lilly's own Zepbound.

FDA approval arrived April 1, 2026 under new drug application (NDA) 220934 as a full approval for chronic weight management in adults with obesity (body mass index, or BMI, of at least 30, a weight-to-height ratio) or overweight (BMI of at least 27) with at least one weight-related comorbid condition such as hypertension or type 2 diabetes [1]. The label carries a boxed warning for thyroid C-cell tumors, a class-wide warning for GLP-1 receptor agonists based on rodent carcinogenicity studies showing medullary thyroid carcinoma, with contraindication in patients having a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. No supplemental approvals have been granted yet, though Phase 3 programs are reading out across type 2 diabetes (ACHIEVE), knee osteoarthritis, hypertension (ATTAIN-Hype), and pediatric obesity [3][4][5]. Because orforglipron is a small molecule rather than a peptide, standard abbreviated new drug application (ANDA) generic pathways will apply once exclusivity expires, but no ANDAs have been filed. Launch pricing has not been publicly disclosed in available SEC filings. The drug is available by prescription through standard pharmacy channels, with no risk evaluation and mitigation strategy (REMS) required.

Picture the gut as a sensor. When food arrives, intestinal L-cells release a hormone called glucagon-like peptide 1, or GLP-1. That hormone does three things that matter here: it tells the pancreas to release insulin when blood sugar is high, tells the stomach to empty more slowly so food lingers, and tells the brain, specifically the hypothalamus and brainstem, that you are full [6]. Patients with obesity and type 2 diabetes often have blunted GLP-1 signaling. Drugs that activate the GLP-1 receptor mimic this signal at pharmacologic levels, producing sustained appetite suppression and improved glucose control. Every previously approved GLP-1 drug is a peptide. Peptides are short chains of amino acids, the same chemistry as the natural hormone, and they get destroyed by stomach acid and digestive enzymes. That is why semaglutide, liraglutide, and tirzepatide are injected, and why oral semaglutide (Rybelsus) requires a permeation enhancer and strict fasting instructions. Orforglipron is different. It is a non-peptide small molecule, roughly the size of a typical oral drug like a statin, that still binds and activates the GLP-1 receptor [7]. This matters for two reasons. First, it survives the gut, so a plain tablet works without special formulation. Second, it is made in standard chemical reactors instead of mammalian cell culture, which collapses per-dose manufacturing cost and expands potential supply.

The registrational data for obesity came from the ATTAIN program. ATTAIN-1 (NCT05869903), a 72-week Phase 3 trial of 3,127 adults with obesity or overweight plus weight-related comorbidities, randomized participants to 6 mg, 12 mg, or 36 mg orforglipron or placebo. The 36 mg maintenance dose produced an average weight reduction of 12.4% (27.3 pounds) versus 0.9% with placebo. Results were published in the New England Journal of Medicine on September 16, 2025 [12]. A supporting systematic review and meta-analysis of 12 mg vs 36 mg dosing confirmed significantly greater weight loss at the higher maintenance dose [9]. ATTAIN-2 (NCT05872620), the companion Phase 3 trial in patients with obesity or overweight plus type 2 diabetes, reported an average weight loss of 10.5% at the highest dose with a 1.8% reduction in HbA1c (a blood test reflecting average blood sugar over the prior three months) at 72 weeks [13]. For context, injectable tirzepatide (Zepbound) at its highest dose produces around 22% weight loss in SURMOUNT-1, so orforglipron is less potent per patient than Lilly's injectable but still clinically meaningful. The side effect profile tracks the broader GLP-1 class. The drug label and class literature identify nausea, constipation, vomiting, fatigue, and diarrhea as the most frequently reported adverse events, with the gastrointestinal effects typically peaking during dose escalation and driving most of the discontinuation seen in trials and real-world practice [11]. On cardiovascular safety, Lilly's ACHIEVE-4 Phase 3 outcomes trial in 2,749 adults with type 2 diabetes at elevated cardiovascular risk met its primary MACE-4 non-inferiority endpoint versus insulin glargine, with a nominal 57% reduction in all-cause mortality in a pre-specified, multiplicity-uncontrolled analysis [14]. A dedicated cardiovascular outcomes trial in patients with atherosclerotic cardiovascular disease and/or chronic kidney disease, ATTAIN-Outcomes (NCT07241390), is also underway [15]. Beyond obesity, the ACHIEVE program (NCT06109311) completed Phase 3 in type 2 diabetes patients inadequately controlled on insulin glargine, with HbA1c change as the primary endpoint [4]. Ongoing Phase 3 trials cover knee osteoarthritis in patients with obesity (NCT07153471) [3], a prevention study in overweight patients at risk of progression to class 1 obesity (NCT07794579) [5], and a pediatric platform (NCT06672549). The hypertension program (ATTAIN-Hype) remains active.

Foundayo enters a market dominated by two injectable franchises: Novo Nordisk's semaglutide (Wegovy for obesity, Ozempic for diabetes, Rybelsus oral for diabetes only) and Lilly's own tirzepatide (Zepbound for obesity, Mounjaro for diabetes). Head-to-head on efficacy alone, tirzepatide produces greater weight loss, roughly 22% at the highest dose versus 12.4% for orforglipron in ATTAIN-1 [12]. That comparison misses the actual constraint on GLP-1 adoption, which has not been efficacy. It has been supply, cold-chain logistics, injection resistance, and cost. A once-daily pill without food or fluid restrictions removes the three biggest adoption barriers for primary care prescribing. Rybelsus, the only approved oral GLP-1 before Foundayo, requires patients to take it on an empty stomach with a small sip of water and wait 30 minutes before eating or drinking anything else. Real-world adherence has been predictably poor. Orforglipron carries no such restriction because it does not rely on a permeation enhancer to cross the gut wall [7]. On pricing, Lilly has not disclosed Foundayo's wholesale acquisition cost (WAC) in available filings. For reference, injectable comparator WACs are roughly $1,349 per month for Wegovy and $1,060 per month for Zepbound, which bounds the plausible launch range absent a strategic undercut. The patent situation favors Lilly in the near term. Composition-of-matter patents on new chemical entities typically grant 15 to 20 years of exclusivity from filing. Lilly's original orforglipron patent family dates to the mid-2010s. Specific expiry dates have not been publicly consolidated, but no ANDAs have been filed. The real competitive threats are not generics but next-generation oral GLP-1s and dual GLP-1/GIP agonists in development at Novo Nordisk (amycretin, higher-dose oral semaglutide), Structure Therapeutics (aleniglipron/GSBR-1290), Terns Pharmaceuticals (TERN-601), and other sponsors tracked across the ClinicalTrials.gov registry. Pfizer's oral GLP-1 danuglipron was discontinued in 2025.

The pre-computed probability of success score of 94% is largely a bookkeeping artifact of the fact that orforglipron is already approved. The genuine remaining uncertainty is around label expansion. Lilly's sponsor track record contributes a 1.30x multiplier, and that is earned: the model counts 17 of 17 recent Phase 3 trials from Lilly as successful. Two other factors in the current model understate the actual de-risking and have been corrected in this writeup. The GLP-1 receptor is one of the most heavily validated drug targets in metabolism, with eight-plus approved agonists spanning liraglutide, semaglutide (injectable and oral), exenatide, dulaglutide, albiglutide, lixisenatide, and tirzepatide; target_novelty should credit a maximally de-risked target. And orforglipron itself has a published positive Phase 2 (NEJM 2023) and a published positive Phase 3 (ATTAIN-1, NEJM 2025) [12] in hand before approval; prior_phase_success is a strong positive, not neutral. For a drug with Phase 3 readouts pending or recently reported in type 2 diabetes, hypertension, knee osteoarthritis, and pediatric obesity, the base rate for additional approvals is high. The commercial trajectory hinges on three variables. First, pricing. Lilly has not disclosed Foundayo's wholesale acquisition cost in publicly available filings. Pricing at parity with injectable Zepbound makes convenience the sole advantage; pricing below could position Foundayo as the default initiation therapy. Second, supply ramp. Manufacturing commentary on Lilly's upcoming Q3 2026 10-Q filing will be the first full-quarter view of how fast the oral franchise scales [2]. Third, the type 2 diabetes label. The ACHIEVE readout opens a market larger than obesity, with broader insurance coverage anchored in decades of diabetes GLP-1 use, and the ACHIEVE-4 cardiovascular safety data strengthen that case [14]. Two developments would meaningfully change the thesis. First, a competitor filing an oral GLP-1 with substantially greater efficacy, in the range of 20% weight loss in a pill, would make Foundayo a transitional product. Second, any human post-marketing signal consistent with the rodent thyroid C-cell finding would tighten the regulatory posture across the whole class. Neither looks imminent. The base case is a multi-billion-dollar franchise within three years that cannibalizes some Zepbound share while growing the total GLP-1 pie by reaching patients who refused injections.

FDA Drugs@FDA NDA 220934 label and approval record; Eli Lilly 2024 Form 10-K (2024 total revenue $45.0B, up 32% YoY, Zepbound and Mounjaro named as primary volume drivers); ATTAIN-1 primary publication in the New England Journal of Medicine (NEJMoa2511774, September 16, 2025); ATTAIN-2 publication in The Lancet (2026); Lilly ACHIEVE-4 cardiovascular safety readout (September 2026 press release); ClinicalTrials.gov entries for NCT05869903 (ATTAIN-1), NCT05872620 (ATTAIN-2), NCT06109311 (ACHIEVE T2D), NCT07241390 (ATTAIN-Outcomes CVOT), NCT07153471 (knee OA), NCT07794579 (overweight prevention), and NCT06672549 (pediatric platform); peer-reviewed reviews on orforglipron and the oral small-molecule GLP-1 category (Wietholter 2026, Guo 2026, Singhani 2026); orforglipron drug label and class literature for adverse event framing in place of unverified FAERS counts.